Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 4-amino-1-?-D-arabinofuranosyl-2(1H)-pyrimidinone
- Correlated keywords
- inhibitor inhibit cancer antiviral anti virals nucleoside analog DNA polymerase hydroxyl sugar reside triphosphorylated in vivo ara-CTP araCTP ara CTPs ? ? Ac 1075 Ac1075 Ac-1075 alexan ara-cells cells arabinocytosine arabinoside C arabitin aracytidine aracytin aracytine arafcyt CHXs 3311 CHX3311 CHX-3311 citozar cyclocide cylocide N cytarabin cytarabine cytarabinoside cytosar U cytosine arabinoside depocyt depo-cyt cyte erpalfa iretin NSCs 287459 63878 NSC-287459 NSC-63878 NSC287459 NSC63878 spongocytidine tarabine PFS Us U19920 U19920A 19920 19920A U-19920 U-19920A udicil ara-cytosine competitive leukemias ?-D-arabinofuranoside .beta.-D-arabinofuranoside beta-D-arabinofuranoside b-D-arabinofuranoside 1-.beta.-D-Arabinofuranosylcytosine 1-beta-D-Arabinofuranosylcytosine 1-b-D-Arabinofuranosylcytosine
- Product Overview:
Cytarabine (ara-C) is a nucleoside analog and prodrug form of the DNA polymerase inhibitor ara-CTP.{48724} It is triphosphorylated to ara-CTP by the successive actions of deoxycytidine kinase, deoxycytidylate kinase, and nucleoside diphosphate kinase.{48725} Ara-C inhibits proliferation of HL-60, ML-1, Raji, and Jurkat human leukemia cell lines with IC50 values of 37, 17, 16, and 72 nM, respectively.{48726} It induces cell cycle arrest at the G0/G1 phase in HL-60 cells when used at concentrations of 2.5 and 15 µM.{48724} ara-C (75 mg/kg per day, i.p.) reduces tumor growth and increases tumor caspase-3 activity in an MOLM-13 mouse xenograft model.{48727} It also increases survival and reduces brain herpesvirus titers in infected rats when administered subcutaneously at doses of 80 and 320 mg/kg.{48728} Formulations containing ara-C have been used in the treatment of acute myeloid leukemia.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.